

Steatotic liver disease (SLD), formerly known as fatty liver disease, is the most common chronic liver condition, affecting one in three people in the Americas, including Canada. Characterized by excess fat in the liver, SLD can progress from a benign state to advanced fibrosis and cirrhosis and is strongly linked to increased risks of cardiovascular disease, extra-hepatic cancers, and premature mortality. Despite its rising prevalence, SLD remains largely absent from Canada's public health agenda.
Regional Health – Americas
|15th Jan, 2026
|The Lancet
Regional Health – Americas
|15th Jan, 2026
|The Lancet
Regional Health – Americas
|15th Jan, 2026
|The Lancet
Regional Health – Americas
|15th Jan, 2026
|The Lancet
Regional Health – Americas
|15th Jan, 2026
|The Lancet
Regional Health – Americas
|15th Jan, 2026
|The Lancet
Regional Health – Americas
|15th Jan, 2026
|The Lancet